Assignee
IONIS PHARMACEUTICALS INC
US·261 granted patents·271 pending applications·911 citations·filing 2008–2025
Top patents by PatentIndex Score
532 records- 0198US11299736B1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2020·Granted Apr 12, 2022·3 cites·21 claims
- 0298US11236335B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Feb 1, 2022·6 cites·24 claims
- 0398US10493092B2Antisense compoundsIONIS PHARMACEUTICALS INC·Filed 2016·Granted Dec 3, 2019·28 cites·31 claims
- 0498US9617540B2Compounds and methods for modulating gene expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 11, 2017·26 cites·20 claims
- 0597US11851655B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Dec 26, 2023·3 cites·33 claims
- 0697US11299737B1Compounds and methods for modulating SMN2IONIS PHARMACEUTICALS INC·Filed 2021·Granted Apr 12, 2022·3 cites·32 claims
- 0797US10844379B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2018·Granted Nov 24, 2020·8 cites·20 claims
- 0897US10294477B2Compositions and methods for modulating PKK expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 21, 2019·25 cites·21 claims
- 0997US9957504B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 1, 2018·8 cites·56 claims
- 1097US9605263B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·20 cites·20 claims
- 1197US9353372B2Compositions and their uses directed to huntingtinIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 31, 2016·16 cites·19 claims
- 1297US9321799B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 26, 2016·17 cites·24 claims
- 1396US11834660B2Compositions for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·2 cites·23 claims
- 1496US11149264B2Modified compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2021·Granted Oct 19, 2021·5 cites·29 claims
- 1596US10883104B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jan 5, 2021·5 cites·6 claims
- 1696US10683499B2Compositions and methods for modulating TTR expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Jun 16, 2020·5 cites·53 claims
- 1796US10266825B2Compositions comprising alternating 2′-modified nucleosides for use in gene modulationIONIS PHARMACEUTICALS INC·Filed 2017·Granted Apr 23, 2019·10 cites·21 claims
- 1896US10006027B2Methods for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jun 26, 2018·21 cites·30 claims
- 1996US9932580B2Compositions and methods for modulating HBV expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 3, 2018·5 cites·42 claims
- 2096US9932581B2Compositions and methods for modulating apolipoprotein C-III expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Apr 3, 2018·6 cites·50 claims
- 2196US9695418B2Oligomeric compounds comprising bicyclic nucleosides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2013·Granted Jul 4, 2017·36 cites·17 claims
- 2296US2025346899A1Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2395US11084844B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2018·Granted Aug 10, 2021·8 cites·20 claims
- 2495US10815480B2Modulation of alpha synuclein expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Oct 27, 2020·7 cites·20 claims
- 2595US10407680B2Compounds and methods for reducing Tau expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·12 cites·31 claims
- 2695US10337007B2Oligomeric compounds comprising bicyclic nucleotides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 2, 2019·6 cites·9 claims
- 2795US10087210B2Modified nucleosides, analogs thereof and oligomeric compounds prepared therefromIONIS PHARMACEUTICALS INC·Filed 2016·Granted Oct 2, 2018·39 cites·9 claims
- 2895US9914922B2Oligomeric compounds comprising bicyclic nucleotides and uses thereofIONIS PHARMACEUTICALS INC·Filed 2013·Granted Mar 13, 2018·14 cites·12 claims
- 2995US9714421B2Compositions and methodsIONIS PHARMACEUTICALS INC·Filed 2014·Granted Jul 25, 2017·5 cites·17 claims
- 3095US9567587B2Antisense modulation of GCCR expressionIONIS PHARMACEUTICALS INC·Filed 2014·Granted Feb 14, 2017·30 cites·24 claims
- 3195US9399774B2Modulation of transthyretin expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted Jul 26, 2016·13 cites·40 claims
- 3294US12509684B2Compositions and methods for modulating apolipoprotein C-III expressionIONIS PHARMACEUTICALS INC·Filed 2024·Granted Dec 30, 2025·0 cites·20 claims
- 3394US11732261B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·2 cites·20 claims
- 3494US11613752B2Compositions and methods for modulating PKK expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Mar 28, 2023·2 cites·24 claims
- 3594US10954519B2Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Mar 23, 2021·5 cites·24 claims
- 3694US10570169B2Conjugated antisense compounds and their useIONIS PHARMACEUTICALS INC·Filed 2015·Granted Feb 25, 2020·11 cites·18 claims
- 3794US10538763B2Compounds and methods for modulation of DUX4IONIS PHARMACEUTICALS INC·Filed 2016·Granted Jan 21, 2020·21 cites·17 claims
- 3894US10517953B2Modulators of PCSK9 expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Dec 31, 2019·5 cites·10 claims
- 3994US10344275B2Linkage modified oligomeric compoundsIONIS PHARMACEUTICALS INC·Filed 2018·Granted Jul 9, 2019·8 cites·21 claims
- 4094US10138482B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2017·Granted Nov 27, 2018·11 cites·20 claims
- 4194US9957292B2Compositions and methods for modulating angiopoietin-like 3 expressionIONIS PHARMACEUTICALS INC·Filed 2015·Granted May 1, 2018·11 cites·81 claims
- 4294US9943604B2Targeted therapeutic nucleosides and their useIONIS PHARMACEUTICALS INC·Filed 2014·Granted Apr 17, 2018·9 cites·16 claims
- 4394US9738895B2Oligomeric compounds and methodsIONIS PHARMACEUTICALS INC·Filed 2015·Granted Aug 22, 2017·10 cites·21 claims
- 4494US9340784B2Methods and compositions for modulating alpha-1-antitrypsin expressionIONIS PHARMACEUTICALS INC·Filed 2013·Granted May 17, 2016·11 cites·14 claims
- 4593US12291709B2Compositions and methods for modulating apolipoprotein (a) expressionIONIS PHARMACEUTICALS INC·Filed 2023·Granted May 6, 2025·0 cites·16 claims
- 4693US11713462B2Modulation of GYS1 expressionIONIS PHARMACEUTICALS INC·Filed 2021·Granted Aug 1, 2023·2 cites·17 claims
- 4793US11111494B2Compositions for modulating Ataxin 2 expressionIONIS PHARMACEUTICALS INC·Filed 2019·Granted Sep 7, 2021·4 cites·27 claims
- 4893US10837016B2Modulation of huntingtin expressionIONIS PHARMACEUTICALS INC·Filed 2020·Granted Nov 17, 2020·2 cites·16 claims
- 4993US10815483B2Compositions for modulating C9ORF72 expressionIONIS PHARMACEUTICALS INC·Filed 2018·Granted Oct 27, 2020·4 cites·20 claims
- 5093US10260069B2Selective antisense compounds and uses thereofIONIS PHARMACEUTICALS INC·Filed 2014·Granted Apr 16, 2019·10 cites·12 claims
Showing the top 50 of 532 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IONIS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →